RevBio was awarded a grant from the National Institute on Aging, part of the National Institutes of Health, of up to $3.4 million over the next three years.
Research funded by this grant will focus on the ability for the patented TETRANITE technology to fill gaps in bone, fixate bone fragments and accelerate healing through its osteoconductive capabilities for fractures in the extremities. TETRANITE will be used both as an interoperative fixation aid and as an adjunct to traditional hardware fixation to provide immediate load sharing between bone and metal plate and screw systems.
By providing additional stability, TETRANITE will help achieve better healing and prevent complications and revision surgeries. It can also be injected percutaneously as a minimally invasive stand-alone method of fixation to surgically treat fractures without the need for conventional open reduction internal fixation. This grant will expand upon the pre-clinical research funded by a previous $2 million SBIR Phase II grant from the National Institute on Aging.
“Our pre-clinical studies have demonstrated that TETRANITE is able to redistribute most of the load from plates and screws thereby reducing the likelihood of hardware failure and delayed healing,” said Brittany McDonough, RevBio’s R&D Program Manager. “This adhesive material also provides a resorbable scaffold for the regeneration of bone which accelerates healing within the first few weeks following a traumatic injury.”
RevBio was awarded a grant from the National Institute on Aging, part of the National Institutes of Health, of up to $3.4 million over the next three years.
Research funded by this grant will focus on the ability for the patented TETRANITE technology to fill gaps in bone, fixate bone fragments and accelerate healing through its osteoconductive...
RevBio was awarded a grant from the National Institute on Aging, part of the National Institutes of Health, of up to $3.4 million over the next three years.
Research funded by this grant will focus on the ability for the patented TETRANITE technology to fill gaps in bone, fixate bone fragments and accelerate healing through its osteoconductive capabilities for fractures in the extremities. TETRANITE will be used both as an interoperative fixation aid and as an adjunct to traditional hardware fixation to provide immediate load sharing between bone and metal plate and screw systems.
By providing additional stability, TETRANITE will help achieve better healing and prevent complications and revision surgeries. It can also be injected percutaneously as a minimally invasive stand-alone method of fixation to surgically treat fractures without the need for conventional open reduction internal fixation. This grant will expand upon the pre-clinical research funded by a previous $2 million SBIR Phase II grant from the National Institute on Aging.
“Our pre-clinical studies have demonstrated that TETRANITE is able to redistribute most of the load from plates and screws thereby reducing the likelihood of hardware failure and delayed healing,” said Brittany McDonough, RevBio’s R&D Program Manager. “This adhesive material also provides a resorbable scaffold for the regeneration of bone which accelerates healing within the first few weeks following a traumatic injury.”
Copy to clipboard 
